Related Experiment Videos
Hypertriglyceridemia may be severe in CML patients treated with interferon-alpha
M J Peñarrubia1, J L Steegmann, E Lavilla
1Hematology Department, Hospital de la Princesa, Madrid, Spain.
American Journal of Hematology
|July 1, 1995
Summary
Interferon-alpha (IFN-alpha) treatment for chronic myeloid leukemia (CML) significantly increases triglyceride levels in most patients. This study highlights a notable secondary effect of IFN-alpha therapy, with some patients experiencing severe hypertriglyceridemia.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm.
- Interferon-alpha (IFN-alpha) has been used in CML treatment.
- Hypertriglyceridemia is a potential metabolic complication.
Purpose of the Study:
- To investigate serum triglyceride (TG) levels in CML patients treated with IFN-alpha.
- To determine the impact of IFN-alpha therapy on TG levels.
- To report a potential secondary effect of IFN-alpha in CML.
Main Methods:
- Analysis of serum triglyceride levels.
- Observation of 22 CML patients undergoing IFN-alpha treatment.
- Monitoring TG levels at diagnosis and during therapy.
Main Results:
- One-half of CML patients had hypertriglyceridemia at diagnosis.
- IFN-alpha treatment led to increased TG levels in 90% of patients.
- Four patients (18%) developed TG levels exceeding 1,000 mg/dl, particularly in early treatment months.
Conclusions:
- IFN-alpha therapy is associated with a significant increase in serum triglyceride levels in CML patients.
- This hypertriglyceridemia represents a notable secondary effect of IFN-alpha treatment.
- Early monitoring of TG levels is recommended for CML patients on IFN-alpha therapy.